Neostigmine
- Generic Name
- Neostigmine
- Brand Names
- Bloxiverz, Prevduo, Prostigmin
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N2O2
- CAS Number
- 59-99-4
- Unique Ingredient Identifier
- 3982TWQ96G
Overview
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Background
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Associated Conditions
- Curarization therapy
- Myasthenia Gravis
- Neuromuscular Blockade
- Postoperative Urinary Retention (POUR)
- Acute Colonic Pseudo-Obstruction
- Post-operative intestinal atony
Clinical Trials
FDA Approved Products
Neostigmine Methylsulfate
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2022/06/30
NDC:63323-415
Neostigmine Methylsulfate
Manufacturer:Medical Purchasing Solutions, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/05/03
NDC:71872-7271
neostigmine methylsulfate
Manufacturer:Meitheal Pharmaceuticals Inc.
Route:INTRAVENOUS
Strength:0.51 mg in 1 mL
Approved: 2021/04/05
NDC:71288-500
NEOSTIGMINE METHYLSULFATE
Manufacturer:Medical Purchasing Solutions, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/05/16
NDC:71872-7143
Neostigmine methylsulfate
Manufacturer:Gland Pharma Limited
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2021/02/17
NDC:68083-384
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath